
Philippe Lucas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8113818/publications.pdf Version: 2024-02-01



DHILIDDELLICAS

#	Article	IF	CITATIONS
1	Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: the Canadian context. Journal of Cannabis Research, 2022, 4, .	3.2	5
2	Perspectives on Healing and Recovery from Addiction with Ayahuasca-Based Therapy Among Members of an Indigenous Community in Canada. , 2021, , 171-188.		1
3	The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients. Journal of Cannabis Research, 2021, 3, 34.	3.2	1
4	Self-reported reductions in tobacco and nicotine use following medical cannabis initiation: Results from a cross-sectional survey of authorized medical cannabis patients in Canada. Journal of Substance Abuse Treatment, 2021, 130, 108481.	2.8	6
5	Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study. Pain Medicine, 2021, 22, 727-739.	1.9	45
6	Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada. International Journal of Drug Policy, 2020, 86, 102963.	3.3	11
7	The Medical Cannabis Standards Engagement Evaluation and Dissemination (SEED) project: A community-based research approach to self-regulating medical cannabis dispensaries in Canada. International Journal of Drug Policy, 2020, 78, 102708.	3.3	1
8	Exploring ayahuascaâ€assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug and Alcohol Review, 2019, 38, 781-789.	2.1	60
9	Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduction Journal, 2019, 16, 9.	3.2	94
10	Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. Journal of Psychiatric Research, 2019, 111, 134-139.	3.1	42
11	Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. Journal of Headache and Pain, 2018, 19, 37.	6.0	126
12	Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy, 2017, 42, 30-35.	3.3	202
13	Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. International Journal of Drug Policy, 2017, 47, 1-8.	3.3	36
14	Rationale for cannabis-based interventions in the opioid overdose crisis. Harm Reduction Journal, 2017, 14, 58.	3.2	71
15	Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology, 2016, 30, 601-607.	4.0	46
16	Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review, 2016, 35, 326-333.	2.1	124
17	Barriers to access for Canadians who use cannabis for therapeutic purposes. International Journal of Drug Policy, 2014, 25, 691-699.	3.3	73
18	Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. International Journal of Drug Policy, 2013, 24, 511-516.	3.3	257

PHILIPPE LUCAS

#	Article	IF	CITATIONS
19	Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research and Theory, 2013, 21, 435-442.	1.9	82
20	Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada. Current Drug Abuse Reviews, 2013, 6, 30-42.	3.4	242
21	Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain. Journal of Psychoactive Drugs, 2012, 44, 125-133.	1.7	91
22	It can't hurt to ask; a patient-centered quality of service assessment of health canada's medical cannabis policy and program. Harm Reduction Journal, 2012, 9, 2.	3.2	15
23	Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice. International Journal of Drug Policy, 2009, 20, 296-303.	3.3	23
24	Reprint of: Survey of medicinal cannabis use among childbearing women: Patterns of its use in pregnancy and retroactive self-assessment of its efficacy against â€~morning sickness'. Complementary Therapies in Clinical Practice, 2009, 15, 242-246.	1.7	12